# BDRX earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/BDRX) · [Earnings tab](https://www.lopjlb.com/stock/BDRX?tab=earnings) Updated: 2026-09-11T06:49:52 Quarters analyzed: 7 ## Cross-quarter narrative From 2014 through early 2015 DARA BioSciences emphasized rapid commercial expansion, record revenues and a growing sales force supporting Gelclair, Soltamox and the orphan‑designated KRN5500. Milestones such as a public offering, formulary approvals and Oravig licensing were delivered, while margin and regulatory uncertainties persisted. By late 2015 the company faced product‑launch timing risks for Oravig, inventory write‑offs and a pending Midatech merger. After the 2015 merger, the combined entity shifted focus to the Q‑Sphera platform, cutting costs and extending cash runway but confronting technical manufacturing hurdles, limited market visibility and a small DIPG patient pool. Funding gaps forced termination of the MTD201 program in 2020, and the firm now relies on collaborations and in‑house programs like MTX110, with ongoing regulatory and technical risks. Across the period, commercial demand moved from strong growth to uncertain visibility, regulatory challenges remained steady, and cash‑runway concerns intensified, while new pipeline initiatives emerged and earlier partnership activities resolved. ## Latest CallCard · Q2 Midatech cut costs, extended cash runway to Q1 2023 and progressed several Q‑Sphera programs, but faces technical hurdles, limited DIPG market and partnership terminations. **Guidance:** maintained — Management did not raise or lower guidance, merely reaffirmed cash runway to Q1 2023. **Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.3 Prepared remarks highlighted cost control, cash runway extension and multiple program advances, conveying optimism. ### Demand visibility Moderate visibility with several preclinical milestones and upcoming partner data, but limited patient pool for DIPG. Proof‑of‑concept data for Q‑Sphera 214/216 expected soon, GBM Phase I trial recruitment planned, while DIPG recruitment remains challenging due to ultra‑orphan status. ### Margins / costs Costs halved year‑on‑year, burn rate ~£0.5 m/month. R&D £2 m, admin £1.6 m, net loss just over £3 m; cost reduction driven by closure of Spanish operation and loan repayments. ### Capital allocation Cash ~£12 m provides runway to Q1 2023; focus on in‑house programs. £9 m raised in July added to £4.5 m existing cash; no license‑fee revenue assumed; funds allocated to internal pipeline and partner collaborations. ### Milestones - **Q‑Sphera 214** [on_track]: Proof‑of‑concept delivered; partner in‑vivo studies ongoing, data expected end of month. - **Q‑Sphera 216** [on_track]: Proof‑of‑concept delivered; partner in‑vivo studies ongoing, data expected early next month. - **Q‑Sphera 213** [at_risk]: Data presented Aug; expanded collaboration proposal being prepared, announcement expected in 2‑3 weeks. - **Brexpiprazole formulation** [on_track]: Three‑month product demonstrated; licensee search with Lideri underway, >100 potential partners contacted. - **MTX110 GBM program** [on_track]: Preclinical efficacy shown; Phase I trial recruitment to start in next few months. - **MTX110 DIPG program** [at_risk]: Phase II setup after FDA pre‑meeting; ultra‑orphan patient pool makes recruitment difficult. - **Protein monoclonal antibody Q‑Sphera** [delivered]: Drug loading increased threefold; binding assays successful, opening large‑molecule opportunity. - **Tacrolimus Q‑Sphera** [on_track]: Proof‑of‑concept formulations delivered; partner animal testing data due soon. ### Fears / risks - **Technical risk**: Assay to measure protein dissolution over time remains unresolved. - **Market risk**: DIPG program targets only ~1,000 patients annually, limiting commercial upside. - **Licensing risk**: Reliance on external partners for development costs; no license‑fee revenue assumed. - **Cash runway risk**: Cash sufficient only to Q1 2023; any delay could strain finances. - **Regulatory risk**: Phase I/II trials for GBM and DIPG must secure approvals and meet recruitment timelines. - **Competition risk**: Large‑molecule space has many big‑pharma entrants; success of Q‑Sphera not guaranteed. - **Partnership risk**: Previous collaborations (e.g., Dr Reddy) have terminated, indicating potential partner suitability issues. - **Share‑price risk**: Current shareholder sentiment is disappointed with share price performance despite progress. ### Key quotes > “our current cash is more closer to £12 million, and that gives us a runway into the first quarter of 2023” > “We've delivered proof-of-concept formulations for 214 and 216. Our partners started in vivo animal testing with those formulations, and we should have data on those in the next few weeks.” > “the team in Cardiff, as I said have increased that 3x” > “I'm personally a shareholder. But everybody's a little disappointed at the moment with where the share price is.” ## Quarter one-liners - **2021 Q2:** Midatech cut costs, extended cash runway to Q1 2023 and progressed several Q‑Sphera programs, but faces technical hurdles, limited DIPG market and partnership terminations. - **2020 Q2:** Midatech pivoted from its MTD201 program to a collaboration‑focused Q‑Sphera strategy, raised £5.75m, cut costs, but faces manufacturing, licensing and EU SME uncertainties. - **2015 Q2:** DARA BioSciences reported record Q2 2015 revenue up 142%, highlighted progress on Oravig launch, secured a new KRN5500 patent and FDA development agreement, and said the Midatech merger remains on track. - **2015 Q1:** DARA BioSciences Q1 2015 net revenue $652k (+304% YoY) despite weather‑related sales loss, announced Oravig US licensing, provided $3.7M full‑year guidance for Gelclair/Soltamox, and updated KRN5500 and sales‑force expansion. - **2014 Q4:** DARA BioSciences posted record Q4 revenue, expanded sales reach, launched patient assistance programs, and reported progress on KRN5500 development while seeking FDA label amendment for Soltamox. - **2014 Q3:** DARA BioSciences reported Q3 2014 record net revenues of $598k (330% YoY), driven by Gelclair market leadership and expanding sales force; Soltamox below expectations but pursuing FDA label change; KRN5500 development ongoing. - **2014 Q2:** DARA BioSciences reports record Q2 revenue, expanding sales force, new orphan designation for KRN5500 and a public offering, while noting modest Soltamox sales and awaiting FDA guidance on its lead asset. ## Theme arcs - **Commercial demand** (deteriorating): Early record revenues and sales‑force expansion gave way to limited demand visibility after the 2020 pivot - **Regulatory environment** (stable): Persistent FDA label, orphan designation and trial approvals with ongoing uncertainty - **Margin pressure** (deteriorating): Initial margin optimism eroded by rising COGS and inventory write‑offs - **Capital allocation shift** (new): Transition from product‑centric funding to collaboration‑driven financing and cost cuts in 2020 - **Pipeline development** (new): Introduction of Q‑Sphera platform and MTX110 programs after 2015 - **Technical manufacturing risk** (new): Q‑Sphera printing and CMO scaling challenges surfaced in 2020‑2021 - **Cash runway/funding risk** (deteriorating): Funding gaps led to program termination and cash sufficient only to Q1 2023 - **Partnership/merger activity** (resolved): Midatech merger completed and no longer a forward‑looking risk ## Guidance path 2014 Q2:vague → 2014 Q3:vague → 2014 Q4:vague → 2015 Q1:maintained → 2015 Q2:maintained → 2020 Q2:maintained → 2021 Q2:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/BDRX`